Video

Susan Moore on Adapting a Practice for Oral Oncolytics

Author(s):

Susan Moore, RN, MSN

Susan Moore Oncology Nurse Practitioner/Consultant, MCG Oncology on Adapting a Practice for Use of Oral Oncolytics

Susan Moore, RN, MSN, ANP, AOCN®, Oncology Nurse Practitioner/Consultant, MCG Oncology, Chicago, IL on Adapting a Practice for Use of Oral Oncolytics

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Related Content
peterschreiber.media– stock.adobe.com
November 23rd 2024

Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma

Tovorafenib in Pediatric BRAF-Altered R/R Low-Grade Glioma | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 23rd 2024

Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma

Michael Badruddoja, MD
November 23rd 2024

NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma

peterschreiber.media– stock.adobe.com
November 22nd 2024

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

Urothelial Cancer
November 16th 2024

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Sebastian Kaulitzki – stock.adobe.com
November 14th 2024

2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More